Home

Albert Cha

CIK 1397906 · last filed 2023-09-28

Albert Cha is a corporate insider who has filed 32 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for ASND, was dated Mar 2, 2026. Across all open-market trades the lifetime net is +$41.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $48.3M across reported positions. 4 SEC filings were submitted jointly with Biohaven Pharmaceutical Holding Co Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$48.35M

Companies

7

Total Filings

32

Lifetime Open-Market Net

$41.68M

Filer Profile

Reported Address
505 HAMILTON AVENUE, SUITE 200
PALO ALTO, CA 94301
Related Filers
Biohaven Pharmaceutical Holding Co Ltd. — 4 joint filings, latest 2018-05-03
EDGAR ENGLEMAN — 2 joint filings, latest 2014-11-20
Vivo Ventures Fund V, L.P. — 2 joint filings, latest 2014-11-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KalVista Pharmaceuticals, Inc. (KALV) Delisted Director 1,144,179 $27.00 $30.89M $21.85M 13 2023-09-28
BHVN Director 2,049,545 $12.71 $26.05M $7.99M 3 2018-05-03
VYNE Therapeutics Inc. (MNLO) Delisted Director 2,606,982 — — $5.00M 1 2018-01-29
ACRS Director 4,191,397 $5.32 $22.30M $5.15M 3 2016-07-01
Sierra Oncology, Inc. (DNAI) Delisted Director 2,064,308 — — $3.74M 1 2015-07-21
ALBIREO PHARMA, INC. (BIOD) Delisted Director 51,799 — — -$2.05M 3 2008-03-04
BIOFORM MEDICAL INC (BFRM) Delisted Director 87,410 — — $0 1 2007-11-14

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-02 ASND Notice (144) −2,100 -$508.4K EDGAR
2025-03-04 ASND Notice (144) −1,470 -$223.6K EDGAR
2024-03-05 ASND Notice (144) −658 -$98.7K EDGAR
2023-09-28 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) — $0 EDGAR
2023-09-13 KalVista Pharmaceuticals, Inc. (KALV) Delisted Mixed — -$54.2K EDGAR
2023-09-11 KalVista Pharmaceuticals, Inc. (KALV) Delisted Notice (144) −18,000 -$180.0K EDGAR
2023-09-07 ASND Notice (144) −77,458 -$8.05M EDGAR
2022-10-17 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) — $0 EDGAR
2021-10-01 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) — $0 EDGAR
2020-11-03 KalVista Pharmaceuticals, Inc. (KALV) Delisted Buy (P) +115,686 $1.99M EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.